Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

PDL BioPharma Company Profile (NASDAQ:PDLI)

Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.75 (5.04% upside)

Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)
Show:
DateFirmActionRatingPrice TargetDetailsShare
9/19/2014ZacksUpgradeNeutral -> Outperform$9.50ViewTweet This Rating  Share This Rating on StockTwits
8/20/2014ZacksReiterated RatingNeutral -> Neutral$10.00ViewTweet This Rating  Share This Rating on StockTwits
8/20/2014Cowen and CompanyBoost Price Target$7.00 -> $8.00ViewTweet This Rating  Share This Rating on StockTwits
5/14/2013Piper JaffrayInitiated CoverageNeutral$8.50ViewTweet This Rating  Share This Rating on StockTwits
3/6/2013JPMorgan Chase & Co.Lower Price TargetNeutral$7.00 -> $6.00ViewTweet This Rating  Share This Rating on StockTwits
1/15/2013Credit SuisseDowngradeNeutral -> Underperform$6.50 -> $6.00ViewTweet This Rating  Share This Rating on StockTwits
1/3/2013Janney Montgomery ScottInitiated CoverageNeutral$7.00ViewTweet This Rating  Share This Rating on StockTwits
1/2/2013Janney Montgomery ScottInitiated CoverageNeutralViewTweet This Rating  Share This Rating on StockTwits
12/6/2012Credit SuisseInitiated CoverageNeutralViewTweet This Rating  Share This Rating on StockTwits
11/12/2012Credit SuisseInitiated CoverageNeutral$6.50ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/23/2012 forward)
Discuss PDL BioPharma